Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Possible Relevance of Soluble Luteinizing Hormone Receptor during Development and Adulthood in Boys and Men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Optimal Systemic Treatment of Advanced Bladder Cancer-A Moving Target

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Electrochemotherapy for colorectal cancer using endoscopic electroporation: a phase 1 clinical study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

This study is an investigator-initiated randomized phase II trial focusing on the treatment of advanced biliary tract cancer with either oxaliplatin 50 mg/m2 and gemcitabine 1000 mg/m2 on day 1 in a two-week cycle with capecitabine 650 mg/m2 twice-daily continuously or cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8 in a three-week cycle. One-hundred patients were included. Forty-seven patients received oxaliplatin, gemcitabine, and capecitabine with a median progression-free survival (mPFS) of 5.7 months (95% CI 3.0-7.8) and a median overall survival (mOS) of 8.7 months (95% CI 6.5-11.2). Forty-nine patients received cisplatin and gemcitabine with a mPFS of 7.3 months (95% CI 6.0-8.7) and a mOS of 12.0 months (95% CI 8.3-16.7). This trial confirms a mOS of 12 months with cisplatin and gemcitabine, as found in earlier trials. With a superior tumor control rate of 79% vs. 60% (p = 0.045), a difference in the mPFS of 1.6 months (HR = 0.721, p = 0.1), and a difference in the mOS of 3.3 months (HR = 0.731, p = 0.1), cisplatin and gemcitabine should still be considered the standard first-line treatment for advanced biliary tract cancer.

Original languageEnglish
Article number1975
JournalCancers
Volume12
Issue number7
Pages (from-to)1-10
Number of pages10
ISSN2072-6694
DOIs
Publication statusPublished - 20 Jul 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

    Research areas

  • Biliary tract cancer, Chemotherapy, Cholangiocarcinoma, Cisplatin, Oxaliplatin, Randomized phase II trial

ID: 61900711